Evidence map›Paper›PMID 30892804›Full record

ArticleHepatology research : the official journal of the Japan Society of Hepatology2019

Albumin-bilirubin score indicates liver fibrosis staging and prognosis in patients with chronic hepatitis C.

Koji Fujita, Kyoko Oura, Hirohito Yoneyama, Tingting Shi, Kei Takuma, Mai Nakahara, Tomoko Tadokoro, Takako Nomura, Asahiro Morishita, Kunihiko Tsutsui and 2 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Hepatology research : the official journal of the Japan Society of Hepatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 2 pooled it
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 2 syntheses or guidelines pooled it, 65 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Baseline ALBI Grade Predicts Benefits After Splenectomy for Cirrhotic Patients with Hypersplenism.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2023
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Koji FujitaDepartment of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Miki, Japan.
Kyoko OuraDepartment of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Miki, Japan.
Hirohito YoneyamaDepartment of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Miki, Japan.
Tingting ShiDepartment of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Miki, Japan.
Kei TakumaDepartment of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Miki, Japan.
Mai NakaharaDepartment of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Miki, Japan.
Tomoko TadokoroDepartment of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Miki, Japan.
Takako NomuraDepartment of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Miki, Japan.
Asahiro MorishitaDepartment of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Miki, Japan.
Kunihiko TsutsuiDepartment of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Miki, Japan.
Takashi HimotoDepartment of Medical Technology, Kagawa Prefectural University of Health Sciences, Takamatsu, Japan.
Tsutomu MasakiDepartment of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Miki, Japan.
Kagawa University · JPKagawa Prefectural College of Health Sciences · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimAlbumin-bilirubin (ALBI) grade was investigated to predict prognosis of patients with cirrhosis. It was defined using the ALBI score calculated based on serum total bilirubin and albumin, which represent liver function. The diagnostic accuracy for liver fibrosis staging in patients with chronic hepatitis using the ALBI score has not been investigated well. This study aimed to evaluate the diagnostic abilities of the ALBI score for liver fibrosis staging in chronic hepatitis and cirrhosis in Japanese patients with hepatitis C virus (HCV) infection.

methodsJapanese patients with HCV infection who underwent liver biopsy examinations were enrolled in a retrospective study. Fibrosis staging and activity grading were assessed using the modified METAVIR score. The ALBI score was calculated according to the following equation: Log10 total bilirubin (μmol/L) × 0.66 + albumin (g/L) × (-0.085).

resultsA total of 382 patients were enrolled in this study. The ALBI score differentiated fibrosis stage 4 from 3 and stage 3 from 2 (P < 0.05). When an ALBI score of -2.125 was adopted as a cut-off value, the sensitivity and specificity were 73.2% and 87.1%, respectively, with a positive likelihood ratio of 5.67 to differentiate stage 4 from stages 1-3. Kaplan-Meier analysis showed that smaller ALBI scores at baseline correlated with better hepatocellular carcinoma (HCC)-free and overall survival (P < 0.05).

conclusionsThe ALBI score indicates liver fibrosis staging in Japanese patients with HCV infection. Furthermore, smaller ALBI scores predict better HCC-free survival and overall survival. The ALBI score has the potential to expand its application from cirrhosis to chronic hepatitis.

Indexed as

hepatitis C, chronichepatocellular carcinomaliver cirrhosisprognosis

Identifiers

PMID30892804
PMCPMC6851801
OpenAlexW2922969274

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.